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ABSTRACT  Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent of all 
chronic liver diseases in Japan. The course and prognosis of disease in Japanese patients with 
NAFLD remains unclear. For a period of 5.2±2.4 years, we followed 274 Japanese patients with 
NAFLD who had undergone liver biopsy. The patients were divided into two groups: patients 
with simple steatosis (SS) or nonalcoholic steatohepatitis (NASH) with fibrosis Stages 0-2 (mild-
fibrosis group), and patients having NASH with fibrosis Stages 3-4 (advanced-fibrosis group). 
The course of hepatic disease and cerebro-cardiovascular events was evaluated in these two 
groups.　Survival of the advanced-fibrosis group was lower than that of the mild-fibrosis group 
(p=0.001). In the advanced-fibrosis group, 7 patients (8.5%) experienced cerebro-cardiovascular 
events after diagnosis, and one died. Hepatic disease (9.8%) occurred in 8 patients: 4 with liver 
decompensation, 3 with hepatocellular carcinoma (HCC), and 1 with both liver decompensation 
and HCC. The 3 patients with liver decompensation died; one underwent liver transplantation. 
No patient in the mild-fibrosis group experienced any cerebro-cardiovascular events or hepatic 
disease, and none of these patients died. The advanced-fibrosis group had higher values than 
the mild-fibrosis group for fibrosis marker, HOMA-IR, hemoglobin A1c, leptin, hs-CRP and 
lower platelet count, and had a tendency toward a higher incidence of diabetes mellitus and 
hypertension.　It is important to understand how to diagnosis advance fibrosis NASH among so 
many patients with NAFLD.
 (Accepted on May 22, 2012)
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INTRODUCTION
   Nonalcoholic fatty liver disease (NAFLD) is 
associated with metabolic syndrome (i.e., abdominal 
obesity, hypertension, atherogenic dyslipidemia, and 
dysglycemia). NAFLD may progress to cirrhosis, 
liver failure, or hepatocellular carcinoma (HCC). 
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NAFLD is the most common cause of chronic 
liver disease in Western and Asian countries１）. 
Based on histological disease activity, NAFLD is 
divided into simple steatosis (SS) and nonalcoholic 
steatohepatitis (NASH). SS has a relatively good 
prognosis, while NASH may progress to cirrhosis or 
HCC２，３）. In Japan, lifestyle-related diseases such 
as obesity, diabetes mellitus, hyperlipidemia, and 
hypertension are becoming more prevalent, along 
with NAFLD. There are possible racial differences 
with respect to NAFLD and NASH. Asian patients 
with NAFLD and NASH tend to have lower body 
mass index (BMI) than Western patients, but have 
relatively more severe insulin resistance despite their 
lower BMI４）. The course and prognosis of disease 
in Asian patients with NAFLD remains unclear. 
With the dramatically increasing number of patients 
with NAFLD in Japan, it is important to investigate 
the disease, focusing on identifying patients with 
poorer prognosis to proactively provide thorough 
examination and treatment to those patients. The 
aim of our study was to prospectively evaluate the 
course and prognosis of disease in patients with 
NAFLD by comparing the causes of NAFLD and 
survival between patients with mild fibrosis (SS 
and NASH Stages 0-2) and patients with advanced 
fibrosis (NASH Stages 3-4). The present report 
provides data from the prospective study on the 
course and prognosis of patients with NASH at a 
single tertiary care hospital.
Materials and Methods
PATIENTS
   Of 352 patients with NAFLD who underwent liver 
biopsy at Kawasaki Hospital, Kawasaki Medical 
School College in a 15-year period between April 
1996 and June 2011, 274 were followed up for 
more than 6 months and enrolled in this study. 
These patients were divided into the mild-fibrosis 
group (SS and NASH Stages 0-2; n = 192) and the 
advanced-fibrosis group (NASH Stages 3-4; n = 82) 
(Fig. 1).
Diagnostic criteria
   A diagnosis of NAFLD was made according 
to the following criteria (i) alcohol intake of ≤
20 g/week (ii) hepatitis B surface (HBs) antigen 
negative, hepatitis C virus (HCV) RNA negative, 
with exclusion of autoimmune liver disease, drug-
induced hepatic disorder, and metabolic liver disease 
(e.g., Wilson’s disease, hemochromatosis) and (iii) 
presence of steatosis (>30%) or steatohepatitis. The 
pathological classification proposed by Matteoni 
et al.５） was used to diagnose histological types 1 
and 2 as SS and types 3 and 4 as NASH. Fibrosis 
was graded from Stage 0 to Stage 4 according to 
the staging system proposed by Brunt et al.６）, and 
the study patients were divided into two groups: 
the mild-fibrosis group (SS, NASH Stages 0-2) and 
the advanced-fibrosis group (Stages 3-4). Liver 
inflammation was graded from Grade 0 to Grade 3, 
also according to the grading system proposed by 
Brunt et al.６）.
Fig. 1.　Out of the total (n = 353) patients with liver biopsy-
proven NAFLD, 274 patients were followed up for more than 
6 months, of whom 192 patients had mild-fibrosis group , and 
82 patients had advanced- fibrosis group.
Among the patients in the mild-fibrosis group, there were 
no occurrences of cardiovascular or cerebrovascular 
disease or liver disease, but in the advanced-fibrosis group, 
cardiovascular or cerebrovascular disease was found in 7 
patients, and liver disease was found 8 patients after diagnosis.
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   The demographic information collected and 
clinical data included age, sex, BMI, history 
of  diabetes,  hyperl ipidemia,  hypertension, 
hyperuricemia, and number of complications 
(obesity [BMI ≥ 25], type2 diabetes mellitus, 
hypertension, dyslipidemia and/or hyperuricemia). 
Diabetes mellitus was diagnosed based on the 
following criteria proposed by The Japan Diabetic 
Society: (i) fasting blood glucose ≥ 126 mg/dL; (ii) 
2-h post-75 g oral glucose tolerance test result ≥  200 
mg/dL; (iii) casual blood glucose ≥  200 mg/dL; and 
(iv) hemoglobin A1c (HbA1c) ≥  6.1 or treatment 
with one or more antidiabetics. Dyslipidemia 
was defined as triglyceride >150 and/or low-
density lipoprotein (LDL) cholesterol level >140 or 
treatment with one or more lipid-lowering drugs. 
Hypertension was defined as systolic/diastolic blood 
pressure ≥ 140/90 mmHg or treatment with one or 
more antihypertensives. Hyperuricemia was defined 
as serum uric acid ≥  7.0 mg/dL or pharmacotherapy 
for hyperuricemia. The number of complications 
(obesity [BMI ≥  25], diabetes mellitus, hypertension, 
dyslipidemia and/or hyperuricemia) was determined 
(0 to 5 complications). All patients underwent 
laboratory tests at the time of liver biopsy: alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), γ -glutamyl transpeptidase (γ-GTP), total 
bilirubin (T-Bil), platelet count, fasting glucose, 
hemoglobin A1c, homeostasis model assessment-
insulin resistance (HOMA-IR), leptin, adiponectin, 
hyaluronic acid, type IV collagen 7S, TIMP-1 and 
procollagen peptide, type III (P-III-P). In addition, 
the patients with NAFLD were separated according 
to sex, and baseline variables were compared 
between the mild-fibrosis group and the advanced-
fibrosis group. The patients were followed up by 
blood laboratory examination and body weight 
measurements every one to three months and 
by abdominal computed tomography (CT) scan, 
magnetic resonance imaging (MRI) and abdominal 
ultrasonography every three to twelve months. The 
patients were examined for cerebro-cardiovascular 
events and hepatic disease to evaluate their course 
and prognosis.
   Cerebro-cardiovascular events included cerebral 
infarction, cerebral hemorrhage, and coronary artery 
disease. Hepatic disease included HCC and liver 
decompensation at Child-Pugh class C.
Statistical analysis
   The patients were followed for cerebro-
cardiovascular events and hepatic disease to evaluate 
their course and prognosis adjusted for sex and age. 
Comparisons between groups were performed using 
Student’s t-test or the Wilcoxon rank sum test or 
the χ2-test. Cumulative survival was calculated 
using the Kaplan-Meier method, and the differences 
between the groups were analyzed with the log-
rank test. Univariate and multivariate analyses of 
predictors of survival were assessed using the Cox 
proportional hazards model. A p value less than 
0.05 was considered to be significant. All analyses 
described above were performed using JMP Ver. 
9.0.1 software (SAS Institute Japan, Tokyo, Japan).
RESULTS
   The enrolled patients consisted of 142 men and 
132 women with a mean age of 53.5 ± 14.8 years. 
Among the 274 patients followed for at least 6 
months, the mean follow-up period was 5.2 ± 
2.8 years for the 192 patients in the mild-fibrosis 
group and 4.5 ± 2.3 years for the 82 patients in 
the advanced-fibrosis group. The demographic and 
basic characteristics of the enrolled patients are 
shown in Table 1. The mean age was significantly 
higher in the advanced-fibrosis group (55.7 ± 14.2 
years) than in the mild-fibrosis group (48.2 ± 15.4 
years). There was no significant difference between 
groups in the male/female ratio. The prevalence 
of type 2 diabetes mellitus and hypertension 
were significantly higher in advance-fibrosis 
group. Table2a and Table2b shows comparison 
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of laboratory date and fibrosis maeker. Platelet 
counts were significantly lower and HOMA-IR, 
hemoglobin A1c, and leptin, hs-CRP were higher in 
the advance-fibrosis group. Hyaluronic acid , TIMP-
1, type 4 collagen 7S, P-III-P as fibrosis markers 
were higher in the advanced-fibrosis group.
   The course and prognosis of the patients in the 
mild-fibrosis group and advanced-fibrosis group 
are shown in Figs. 1 and 2, respectively. Among 
the 82 patients with advanced fibrosis, 7 patients 
Table 1.　Comparison of clinicopathological features between mild-ﬁbrosis group and 
advanced- ﬁbrosis group.
SS,NASH(F0-F2)
n=192
NASH(F3,F4)
n=82
Univariate
P-value
Stage
Median follow up
（years）
(SS/F0/F1/F2)
30/10/100/29
5.2±2.8
（0.6-15.3)
(F3/F4)
72/10
4.5±2.3
（0.6-12)
*
0.1021
Age(years)
Sex(female)
Body mass index(Kg/m2)
Diabete
Dyslipidemia
Hypertension
Hyperuricemia
Number of complication
(0/1/2/3/4/5)
48.2±15.4
44.2%
27.2±3.8
29%
78%
24%
24%
8/34/72/53/21/4
55.7±14.2
57%
28.9±5.4
43%
73%
45%
19%
0/11/27/29/13/2
0.0002
0.1083
0.0454
0.0208
0.3510
0.0013
0.3179
0.1320
Table 2a.　Comparison of laboratory date between mild- ﬁbrosis group and advanced-
ﬁbrosis group.
SS,NASH(F0-F2)
n=192
NASH(F3,F4)
n=82
Univariate
P-value
AST（IU/L）
ALT（IU/L）
GGTP（IU/L）
Total bilirunin(mg/dl)
TotalCholesterol(mg/dl)
Platelet count( ×104)
Hemoglobin A1c(%)
Fasting glucose(mg/dl)
HOMA-IR(%)
Leptin(ng/dl)
Iron(ug/dl)
Ferritin(ng/ml)
high sensivity-CRP(ng/dl)
Thioredoxin(ng/dl)
Adiponectin(Male)(ug/dl)
Adiponectin(Female)(ug/dl)
54.8±39.9
90.1±69.2
80.1±67.2
0.8±0.3
210.8±37.9
22.4±5.9
5.6±1.2
107.8±34
3.8±3.8
10.9±8.2
118.5±38.8
187.6±150.1
148.3±101.9
46.3±37.7
5.1±2.1
7.6±4.1
62.8±29.5
90.7±51.4
76.9±66.5
0.9±0.5
208.7±35.1
19.5±6.5
6.0±1.3
110.1±22.2
4.5±3.4
14.1±7.8
123.3±37.1
236.8±192.9
173.4±106.7
49.3±44.7
5.4±4.1
7.4±5.9
<0.0001
0.2824
0.5187
0.0290
0.5791
0.0002
0.0131
0.0354
0.0035
0.0002
0.6437
0.0880
0.0505
0.6447
0.4778
0.0678
AST,aspartate aminotransferase; ALT, alanine aminotransferase; GGTP, gamma-
glutamyl transpeptidase; HOMA-IR,homeostasis model assessment-insulin resistance
Table 2b.　Comparison of ﬁbrosis markers between mild-ﬁbrosis group and advanced-
ﬁbrosis group.
SS,NASH(F0-F2)
n=192
NASH(F3,F4)
n=82
Univariate
P-value
Hyaluronic acid(ng/ml)
P-Ⅲ-P(U/ml)
TIMP-1(ng/ml)
Type4 collagen7S(ng/ml)
38.3±43.6
0.7±0.2
180±58.9
3.9±0.8
88.9±113.9
0.8±0.3
199±49.8
5.1±2
<0.0001
0.0126
0.0007
<0.0001
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experienced at cerebro-cardiovascular event during 
the post-diagnosis follow-up period (mean duration: 
5.2 years). The reported events included cerebral 
infarction, or cerebral hemorrhage in 4 patients, 
and angina pectoris or myocardial infarction in 
3 patients. Of these patients, the patient with 
myocardial infarction died. In addition, hepatic 
disease was found in 8 patients: 4 with liver 
decompensation, 3 with HCC, and 1 with both 
liver decompensation and HCC. Subsequently, 
the 3 patients with liver decompensation died, and 
the remaining 1 patient underwent living donor 
liver transplantation. None of the patients in the 
mild-fibrosis group experienced any cerebro-
cardiovascular events or liver-related disease 
during the follow-up period (mean duration: 4.5 
years). These results indicate that the patients with 
advanced fibrosis were significantly more likely 
Fig. 2.　Among the 82 patients with advanced fibrosis group, 7 patients 
experienced at cerebro-cardiovascular (cerebral infarction, or cerebral 
hemorrhage in 4 patients, and angina pectoris or myocardial infarction in 3 
patients). Of these patients, one patient with myocardial infarction died .Hepatic 
disease was found in 8 patients: 4 with liver decompensation, 3 with HCC, and 1 
with both liver decompensation and HCC. Subsequently, the 3 patients with liver 
decompensation died, and the remaining 1 patient underwent living donor liver 
transplantation.
Fig. 3.　Based on the log-rank test, the prevalence of cardiovascular and 
cerebrovascular disease among the patients with advanced-fibrosis group was 
significantly higher (p < 0.0001) than mild fibrosis group.
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Fig. 4.　Based on the log-rank test, the prevalence of liver disease among 
patients with advanced-fibrosis group, was significantly higher (p < 0.0016) than 
in the patients with mild-fibrosis group.
Fig. 5.　Based on the log-rank test, the survival ratio among the patients 
with mild-fibrosis group was significantly higher (p < 0.0012) compared with 
advanced-fibrosis group.
to experience cardiovascular events (p < 0.0001), 
hepatic disease (p = 0.0016), or all-cause mortality, 
and they had poorer prognosis (p = 0.0012) than the 
patients in the mild-fibrosis group adjusted for sex 
and age (Figs. 3 to 5).
DISCUSSION
   We assessed the prognosis and outcome of NASH 
patients stratified by the stage of fibrosis. NAFLD 
is the most common cause of chronic liver disease 
in Western and Asian countries１）. But the course 
and prognosis of the Japanese NASH patients 
remains unclear. In Western country, various reports 
have been published on the outcomes of NASH 
and NAFLD. Regarding the progression from SS 
to NASH, Ekstedt et al.７） conducted a controlled 
cohort study and found that during a 13.7-year 
follow-up period, patients with SS had a mortality 
rate similar to the general population, but patients 
with NASH had a significantly higher mortality 
rate. Teli et al.２） and Dam-Larsen et al.３） reported 
that patients who had NAFLD without fibrosis had 
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a benign course. However, in a previous study８）, in 
which 44 patients with biopsy-proven NAFLD had 
their liver biopsies repeated at month 36, among 
13 patients with SS at first biopsy, 8 (61%) had 
developed borderline NASH or NASH by the time 
of the second biopsy. Argo et al.９） reported on 
their systematic analysis of 221 cases of biopsy-
proven NASH. In total, 38% of the study patients 
had progressive fibrosis, 21% improved, and 41% 
remained stable over a mean follow-up period of 5.3 
years. The study of Angulo et al.10）, who observed 
the outcomes of SS in 342 patients for more than 
5 years, revealed that SS progressed to cirrhosis in 
only 0.7% of the patients, and NASH progressed 
to cirrhosis in 10.8% of the patients (mean follow-
up duration: 15.5 years) ７－８，10－13）. In fact, almost 
all patients with SS have a benign course, but some 
cases of NASH may progress to cirrhosis or HCC.
   In Japanese patients with NASH, only a few 
reports have been published. Yastuji et al.15） and 
Hashimoto et al.15，16） have reported on 68 cases of 
cirrhotic NASH in Japanese patients, with a mean 
follow-up period of 41 months. The outcome of 
patients having NASH with cirrhosis was a 5-year 
survival rate of 75.2%. Multivariate analysis 
showed that HCC and a high Child-Pugh score were 
significant risk factors for mortality in patients with 
NASH who developed cirrhosis.
   Additionally, with respect to the cause of death 
in a community-based cohort of 420 patients 
with NAFLD who were followed for a mean 
period of 7.6 years (range, 0.1 to 23.5 years), the 
rate of death from the most common cause of 
cardiovascular disease was revealed to be higher 
among patients with NASH or NASH cirrhosis 
than among the general population１）. In another 
study８）, cardiovascular disease was found to be the 
most frequent cause of death in 173 patients with 
biopsy-proven NAFLD who were followed for 13 
years. Soderberg et al.11） confirmed that NASH was 
associated with increased mortality from all causes 
and from cardiovascular disease and liver-related 
causes among patients with NAFLD who were 
followed for a mean period of 21 years11）. 
   A systematic review and meta-analysis of seven 
cross-sectional studies (3497 subjects) confirmed 
that NAFLD diagnosed on ultrasonography is 
strongly associated with increased carotid-artery 
intima-medial thickness (carotid IMT) and an 
increased prevalence of carotid atherosclerotic 
plaque17）. Carotid IMT has been independently 
associated with future risk for ischemic coronary 
events and stroke in middle-aged and older 
individuals18）. Targher et al.19） found that carotid 
IMT was greates t  in  pat ients  wi th  NASH, 
intermediate in those with SS, and lowest in healthy 
controls matched for age, sex, and BMI. In addition, 
the histologic severity of NASH was associated 
with the degree of IMT, independent of classic 
cardiovascular risk factors, insulin resistance, and 
metabolic syndrome. 
   In the present study, the advanced-fibrosis group 
was associated with a higher incidence of cerebro-
cardiovascular events, and hepatic disease, and 
a higher mortality rate. In contrast, no cerebro-
cardiovascular events or hepatic disease were 
reported during the course of the study among the 
192 patients in the mild-fibrosis group. For this 
reason, it is important that we find the biomarkers 
that can predict the NASH with advanced fibrosis 
among NAFLD. In this study, the hallmark of 
disease progression to advance stage NASH patients 
was increasing fibrosis marker, as reflected by 
the disease stage. In addition we have previously 
reported that high-sensitivity C-reactive protein (hs-
CRP), adiponectin (in men) and leptin (in women) 
seem to be good non-invasive markers of NASH; 
these markers can be used to detect up to 90% of 
patients with NASH20）. Moreover, a number of 
studies19，21） have reported that circulation levels of 
several inflammatory markers (e.g., hs-CRP, TNF-
α , plasminogen activator inhibitor-1 (PAI-1), 
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fibrinogen), adipocytocin (e.g., adiponectin, leptin), 
and oxidative stress markers (e.g., thioredoxin, 
nitrotyrosine) are highest in patients with NASH 
and are associated with cardiovascular disease. 
Targher et al.19） showed that the severity of liver 
histology found in NASH was strongly associated 
with increasing plasma concentrations of hs-
CRP, PAI-1, and fibrinogen, and with decreasing 
plasma concentrations of adiponectin. Additionally, 
NASH and visceral adiposity have been used as 
cardiovascular risk biomarkers independent of 
potential confounders. In adult men, NASH has 
been found to predict a tendency toward atherogenic 
risk in a manner that is partly independent of the 
contribution of visceral adiposity21）.
   In conclusion, NASH with advanced fibrosis may 
induce cardiovascular events and hepatic disease, 
and is associated with increased mortality. For these 
reasons, it is essential to identify high-risk patients 
and proactively provide thorough examination 
and treatment. Patients with NASH who have 
advanced fibrosis should be followed, not only to 
monitor their liver condition, but also to provide 
systemic surveillance to reduce the incidence of 
cerebro-cardiovascular events in this population. 
It is important to understand how to diagnosis 
advance fibrosis NASH among so many patients 
with NAFLD. For this purpose, it is necessary to 
find biomarkers that can predict the development 
of NASH with advanced fibrosis in Japanese 
patients with NAFLD. Further research is needed 
to investigate the process of disease progression in 
NASH.
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